TY - JOUR
T1 - Hereditary prostate cancer – Primetime for genetic testing?
AU - Heidegger, Isabel
AU - Tsaur, Igor
AU - Borgmann, Hendrik
AU - Surcel, Christian
AU - Kretschmer, Alexander
AU - Mathieu, Romain
AU - Visschere, Pieter De
AU - Valerio, Massimo
AU - van den Bergh, Roderick C.N.
AU - Ost, Piet
AU - Tilki, Derya
AU - Gandaglia, Giorgio
AU - Ploussard, Guillaume
PY - 2019/12
Y1 - 2019/12
N2 - Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5–15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly, we discuss the impact of genetic testing in personalized therapy in advanced stages of the disease.
AB - Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5–15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly, we discuss the impact of genetic testing in personalized therapy in advanced stages of the disease.
KW - Genetic testing
KW - Hereditary
KW - Precision oncology
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85075495923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075495923&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2019.101927
DO - 10.1016/j.ctrv.2019.101927
M3 - Review article
C2 - 31783313
AN - SCOPUS:85075495923
VL - 81
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
M1 - 101927
ER -